Dick Gregory M, Bratz Ian N, Borbouse Léna, Payne Gregory A, Dincer U Deniz, Knudson Jarrod D, Rogers Paul A, Tune Johnathan D
Department of Exercise Physiology, Center for Interdisciplinary Research in Cardiovascular Sciences, West Virginia University School of Medicine, Morgantown, WV, USA.
Am J Physiol Heart Circ Physiol. 2008 May;294(5):H2371-81. doi: 10.1152/ajpheart.01279.2007. Epub 2008 Mar 28.
We previously demonstrated a role for voltage-dependent K(+) (K(V)) channels in coronary vasodilation elicited by myocardial metabolism and exogenous H(2)O(2), as responses were attenuated by the K(V) channel blocker 4-aminopyridine (4-AP). Here we tested the hypothesis that K(V) channels participate in coronary reactive hyperemia and examined the role of K(V) channels in responses to nitric oxide (NO) and adenosine, two putative mediators. Reactive hyperemia (30-s occlusion) was measured in open-chest dogs before and during 4-AP treatment [intracoronary (ic), plasma concentration 0.3 mM]. 4-AP reduced baseline flow 34 +/- 5% and inhibited hyperemic volume 32 +/- 5%. Administration of 8-phenyltheophylline (8-PT; 0.3 mM ic or 5 mg/kg iv) or N(G)-nitro-L-arginine methyl ester (L-NAME; 1 mg/min ic) inhibited early and late portions of hyperemic flow, supporting roles for adenosine and NO. 4-AP further inhibited hyperemia in the presence of 8-PT or L-NAME. Adenosine-induced blood flow responses were attenuated by 4-AP (52 +/- 6% block at 9 microg/min). Dilation of arterioles to adenosine was attenuated by 0.3 mM 4-AP and 1 microM correolide, a selective K(V)1 antagonist (76 +/- 7% and 47 +/- 2% block, respectively, at 1 microM). Dilation in response to sodium nitroprusside, an NO donor, was attenuated by 4-AP in vivo (41 +/- 6% block at 10 microg/min) and by correolide in vitro (29 +/- 4% block at 1 microM). K(V) current in smooth muscle cells was inhibited by 4-AP (IC(50) 1.1 +/- 0.1 mM) and virtually eliminated by correolide. Expression of mRNA for K(V)1 family members was detected in coronary arteries. Our data indicate that K(V) channels play an important role in regulating resting coronary blood flow, determining duration of reactive hyperemia, and mediating adenosine- and NO-induced vasodilation.
我们先前证明,电压依赖性钾离子(K(V))通道在心肌代谢和外源性过氧化氢引发的冠状动脉舒张中发挥作用,因为钾离子通道阻滞剂4-氨基吡啶(4-AP)会减弱这种反应。在此,我们检验了K(V)通道参与冠状动脉反应性充血的假说,并研究了K(V)通道在对一氧化氮(NO)和腺苷这两种假定介质的反应中的作用。在开胸犬身上,于4-AP治疗前及治疗期间[冠状动脉内(ic)给药,血浆浓度0.3 mM]测量反应性充血(30秒阻塞)情况。4-AP使基础血流量降低34±5%,并抑制充血量32±5%。给予8-苯基茶碱(8-PT;0.3 mM冠状动脉内给药或5 mg/kg静脉注射)或N(G)-硝基-L-精氨酸甲酯(L-NAME;1 mg/min冠状动脉内给药)可抑制充血血流的早期和晚期部分,支持腺苷和NO的作用。在存在8-PT或L-NAME的情况下,4-AP进一步抑制充血。4-AP使腺苷诱导的血流反应减弱(在9 μg/min时阻断52±6%)。0.3 mM 4-AP和1 μM correolide(一种选择性K(V)1拮抗剂)使小动脉对腺苷的舒张减弱(在1 μM时分别阻断76±7%和47±2%)。在体内,4-AP使对NO供体硝普钠的舒张反应减弱(在10 μg/min时阻断41±6%),在体外,correolide使这种舒张反应减弱(在1 μM时阻断29±4%)。4-AP抑制平滑肌细胞中的K(V)电流(半数抑制浓度[IC(50)]为1.1±0.1 mM),而correolide几乎完全消除该电流。在冠状动脉中检测到K(V)1家族成员的mRNA表达。我们的数据表明,K(V)通道在调节静息冠状动脉血流量、确定反应性充血持续时间以及介导腺苷和NO诱导的血管舒张中起重要作用。